Advertisement
Screener

CULLINAN THERAPEUTICS, INC. (CGEM) Graph

CGEM Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Revenue (m); Research and development $44.44M; Operating expenses $57.25M; Income tax (m).
  • 2026-03-31: Revenue (m); Research and development $42.12M; Operating expenses $53.70M; Income tax (m).
  • 2025-12-31: Revenue (m); Research and development $42.95M*; Operating expenses $55.26M*; Income tax (m).
  • 2025-09-30: Revenue (m); Research and development $41.97M; Operating expenses $55.59M; Income tax (m).

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30(m)$44.44M$57.25M(m)(m)
2026-03-31(m)$42.12M$53.70M(m)(m)
2025-12-31(m)$42.95M*$55.26M*(m)-$50.71M*
2025-09-30(m)$41.97M$55.59M(m)-$50.61M
2025-06-30(m)$61.03M$75.80M(m)-$70.06M
2025-03-31(m)$41.46M$55.00M(m)-$48.50M
2024-09-30(m)$35.51M$48.85M(m)-$40.56M
2024-06-30(m)$36.26M$50.03M(m)-$42.03M
2024-03-31(m)$30.65M$42.99M(m)-$37.15M
2023-09-30(m)$33.82M$44.80M$0.00-$39.18M
2023-06-30(m)$27.39M$37.60M$0.00-$32.21M
2023-03-31(m)$52.10M$62.76M$0.00-$57.96M
2022-12-31$0.00*(m)(m)(m)(m)
2022-09-30$0.00$19.68M$29.77M-$2.52M-$24.80M
2022-06-30$0.00$26.41M$37.11M$66.07M$174.90M
2022-03-31$0.00$24.54M$32.66M-$19.57M-$12.10M
2021-09-30$0.00$12.68M$18.38M$0.00-$17.35M
2021-06-30$0.00$11.78M$16.60M$0.00-$15.64M
2021-03-31$18.94M$12.41M$17.57M$0.00-$70.00K
2020-09-30(m)$9.91M$11.50M$0.00-$9.86M
2020-06-30(m)$12.50M$14.12M$0.00-$8.62M
2020-03-31(m)$4.17M$5.54M$0.00-$4.97M

Revenue and expense 6 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30(m)$86.56M$110.95M(m)(m)
2025-06-30(m)$102.49M$130.79M(m)-$118.56M
2024-06-30(m)$66.91M$93.02M(m)-$79.18M
2023-06-30(m)$79.49M$100.36M$0.00-$90.18M
2022-06-30$0.00$50.95M$69.76M$46.50M$162.80M
2021-06-30$18.94M$24.19M$34.17M$0.00-$15.71M
2020-06-30(m)$16.67M$19.66M$0.00-$13.60M

Revenue and expense 9 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-09-30(m)$144.46M$186.39M(m)-$169.17M
2024-09-30(m)$102.41M$141.87M(m)-$119.74M
2023-09-30(m)$113.31M$145.16M$0.00-$129.36M
2022-09-30$0.00$70.63M$99.53M$43.98M$138.00M
2021-09-30$18.94M$36.87M$52.55M$0.00-$33.06M
2020-09-30(m)$26.58M$31.16M$0.00-$23.45M

Revenue and expense 12 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31(m)$187.40M$241.65M$0.00-$219.88M
2024-12-31(m)$142.90M$196.92M$117.00K-$167.57M
2023-12-31(m)$148.16M$190.65M-$14.12M-$155.10M
2022-12-31$0.00$91.95M$132.14M$42.12M$111.21M
2021-12-31$18.94M$57.75M$86.90M$0.00-$65.57M
2020-12-31$0.00$43.21M$60.34M(m)-$51.80M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Monte Rosa Therapeutics, Inc. (GLUE)United States$1.002B-12.81
Odyssey Therapeutics, Inc. (ODTX)United States$0.960B
MeiraGTx Holdings plc (MGTX)United States$1.061B16.10
Vor Biopharma Inc. (VOR)United States$1.091B1.60
Sana Biotechnology, Inc. (SANA)United States$0.886B-4.92
Candel Therapeutics, Inc. (CADL)United States$0.885B-8.86
Attovia Therapeutics, Inc. (ATTO)United States$0.828B
Solid Biosciences Inc. (SLDB)United States$0.802B-5.07
Replimune Group, Inc. (REPL)United States$1.186B-3.13
4D Molecular Therapeutics, Inc. (FDMT)United States$0.733B-4.10